COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials

Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc CMPS reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses.

In numbers:

  • Cash and cash equivalents totaled $117.1 million as of March 31, 2023 compared to $143.2 million as of 31 Dec. 2022.

  • Net loss was $24.2 million ($0.57 loss per share) compared to $21.2 million ($0.50 loss per share) in the first quarter of 2022.

  • R&D expenses were $19.0 million compared to $15.4 million in the same period in 2022.

  • G&A expenses were $12.8 million compared to $10.1 million in the same period in 2022.

During the second quarter so far, COMPASS raised an extra $26.9 million net cash through ATM facility to date. The company further announced an expected $22-$30 million net cash expense for operating activities for the second quarter, and a $85-$110 million yearly operating expense.

See also: COMPASS Pathways Shares Q4 & Year-End 2022 Financials, Advances Phase 3 Psilocybin Trials

CEO Kabir Nath says COMPASS’ two Phase 3 multi-site psilocybin trials for Treatment-Resistant Depression (TRD) are currently underway and on track, “indicating that with the necessary approvals and licenses in place, these sites can now focus completely on training and recruitment.”

Specifically, trial 1 (or COMP 005) is set to provide a single-dose monotherapy to some 255 participants, with topline data expected in the summer of 2024; and trial 2 (or COMP 006) is a fixed repeat-dose monotherapy assessed in 568 subjects, of which topline data is expected by mid-2025.

Nath also mentioned the company’s progress in laying the commercial groundwork for COMP360 through AMA’s approval of a CPT III code describing the support services required in psychedelic administration.

Additionally, COMPASS has continued to investigate COMP360 psilocybin therapy in preclinical and clinical trials, including those on anorexia-nervosa and PTSD, during this first quarter of 2023.

“It has been a quarter of steady, strong progress, including productive, ongoing dialogue about the design of our pivotal trials with FDA,” Nath concluded.

Photo: Benzinga edit with photo by anaterate and sergeitokmakov on Pixabay.

CMPSCompass Pathways PLC
$3.75-5.98%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
11.21
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!

Comments
Loading...